Vilija Oke

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: QJM - MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS. 2024;117(8):581-588
Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection
Nln I; Shum J; Ghodke-Puranik Y; Tipon R; Triese D; Amin S; Makol A; Osborn T; Chowdhary V; Thanarajasingam U; Muskardin TLW; Oke V; Gunnarsson I; Zickert A; Zervou MI; Boumpas DT; Svenungsson E; Goulielmos GN; Niewold TB
Article: RHEUMATOLOGY. 2024;:keae134
Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients
Elbagir S; Mohammed NA; Oke V; Larsson A; Nilsson J; Elshafie A; Elagib EM; Nur MAM; Gunnarsson I; Svenungsson E; Ronnelid J
Journal article: REVUE DU RHUMATISME (EDITION FRANCAISE). 2023;90:a170-a171
Améliorations cliniquement significatives des critères-patient sous guselkumab chez les patients atteints de rhumatisme psoriasique actif en réponse inadéquate aux anti-TNF : résultats à un an d’une étude de phase 3b, randomisée, contrôlée (COSMOS)
Gossec L; Baraliakos X; Galloway J; Kristensen LE; Oke V; Sfikakis P; Rampakakis E; Sharaf M; Lavie F; Mcinnes IB
Article: LUPUS SCIENCE AND MEDICINE. 2022;9(1):e000744
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
Hayry A; Faustini F; Zickert A; Larsson A; Niewold TB; Svenungsson E; Oke V; Gunnarsson I
Article: ACR OPEN RHEUMATOLOGY. 2022;4(1):27-39
Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA-DRB1 Genotype Associations and Immunological and Clinical Manifestations
Diaz-Gallo L-M; Oke V; Lundstrom E; Elvin K; Wu YL; Eketjall S; Zickert A; Gustafsson JT; Jonsen A; Leonard D; Birmingham DJ; Nordmark G; Bengtsson AA; Ronnblom L; Gunnarsson I; Yu C-Y; Padyukov L; Svenungsson E
Article: ARTHRITIS RESEARCH & THERAPY. 2021;23(1):132
Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE
Niewold TB; Meves A; Lehman JS; Popovic-Silwerfeldt K; Hayry A; Soderlund-Matell T; Charlesworth CM; Madden B; Lundberg IE; Wahren-Herlenius M; Svenungsson E; Oke V
Article: RHEUMATOLOGY. 2021;60(3):1445-1455
Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment
Bjork A; Rodrigues RDS; Andersson ER; Sepulveda JIR; Mofors J; Kvarnstrom M; Oke V; Svenungsson E; Gunnarsson I; Wahren-Herlenius M
Article: JOURNAL OF RHEUMATOLOGY. 2020;47(6):865-875
Sjogren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State
Ruacho G; Kvarnstrom M; Zickert A; Oke V; Ronnelid J; Eketjall S; Elvin K; Gunnarsson I; Svenungsson E
Article: ARTHRITIS RESEARCH & THERAPY. 2019;21(1):107
High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus
Oke V; Gunnarsson I; Dorschner J; Eketjaell S; Zickert A; Niewold TB; Svenungsson E
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:1029
Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients
Idborg H; Zandian A; Ossipova E; Wigren E; Preger C; Mobarrez F; Checa A; Sohrabian A; Pucholt P; Sandling JK; Fernandes-Cerqueira C; Ronnelid J; Oke V; Grosso G; Kvarnstrom M; Larsson A; Wheelock CE; Syvanen A-C; Ronnblom L; Kultima K; Persson H; Graslund S; Gunnarsson I; Nilsson P; Svenungsson E; Jakobsson P-J
Article: LUPUS SCIENCE AND MEDICINE. 2018;5(1):e000260
TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
Idborg H; Eketjall S; Pettersson S; Gustafsson JT; Zickert A; Kvarnstrom M; Oke V; Jakobsson P-J; Gunnarsson I; Svenungsson E
Article: ARTHRITIS RESEARCH & THERAPY. 2017;19(1):139
IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
Oke V; Brauner S; Larsson A; Gustafsson J; Zickert A; Gunnarsson I; Svenungsson E
Article: LUPUS SCIENCE AND MEDICINE. 2016;3(1):e000170
Interferon (IFN)-λ is a potential mediator in lupus nephritis.
Zickert A; Oke V; Parodis I; Svenungsson E; Sundström Y; Gunnarsson I
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2011;131(8):1622-1630
Photoprovocation in Cutaneous Lupus Erythematosus: A Multicenter Study Evaluating a Standardized Protocol
Kuhn A; Wozniacka A; Szepietowski JC; Glaeser R; Lehmann P; Haust M; Sysa-Jedrzejowska A; Reich A; Oke V; Huegel R; Calderon C; de Vries DE; Nyberg F
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2009;129(8):2000-2010
High Ro52 Expression in Spontaneous and UV-Induced Cutaneous Inflammation
Oke V; Vassilaki I; Espinosa A; Strandberg L; Kuchroo VK; Nyberg F; Wahren-Herlenius M
Article: EXPERIMENTAL CELL RESEARCH. 2008;314(20):3605-3613
The autoantigen Ro52 is an E3 ligase resident in the cytoplasm but enters the nucleus upon cellular exposure to nitric oxide
Espinosa A; Oke V; Elfving A; Nyberg F; Covacu R; Wahren-Herlenius M
Article: LUPUS. 2007;16(10):794-802
Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus
Barkauskaite V; Ek M; Popovic K; Harris HE; Wahren-Herlenius M; Nyberg F

Alla övriga publikationer

Conference publication: 2024;:1134-1135
POS1323 IL-16 EXPRESSION IN RENAL IGA VASCULITIS AND THROMBOTIC MICROANGIOPATHY - A PILOT STUDY ON A POSSIBLE NOVEL ACTIVITY BIOMARKER
Häyry A; Oke V; Larsson A; Svenungsson E; Gunnarsson I; Faustini F
Conference publication: 2024;:36.2-3637
OP0091 INTERLEUKIN (IL)-16 IN PLASMA AND URINE IN ANTI – NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS
Juto A; Faustini F; Häyry A; Larsson A; Malmström V; Bruchfeld A; Antovic A; Oke V; Gunnarsson I
Conference publication: 2024;:a49.2-a4a50
P10 IL-16 expression in kidney biopsies from patients with SLE- and antiphosholipid syndrome- associated renal thrombotic microangiopathy and renal IgA vasculitis
Häyry A; Oke V; Svenungsson E; Faustini F; Gunnarsson I
Conference publication: 2024;:a55-a56
P18 Proteomic analysis of cutaneous lupus erythematosus (CLE) dermal infiltrates and control skin reveals differentially upregulated and downregulated pathways
Niewold TB; Meves A; Lehman J; Dasari S; Popovic-Silwerfeldt K; Charlesworth C; Madden B; Svenungsson E; Oke V
Conference publication: 2024;:a29.2-a2a30
O30 Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients
Elbagir S; Mohammed NA; Oke V; Larsson A; Nilsson J; Elshafie A; Elagib EM; Nur MA; Gunnarsson I; Svenungsson E; Rönnelid J
Conference publication: 2023;:a101.1-a1a101
LP-016 Anti-histone and anti-nucleosome antibodies, rather than anti-dsDNA antibodies are associated with interferon-induced biomarkers in Sudanese and Swedish SLE patients
Elbagir S; Mohammed NA; Oke V; Zickert A; Svanqvist A; Westerberg CM; Larsson A; Nilsson J; Elshafie A; Elagib EM; Nur MA; Gunnarsson I; Svenungsson E; Rönnelid J
Conference publication: 2023;:a59.1-a5a59
LSO-039 Proteomic analysis of cutaneous lupus erythematosus and dermatomyositis dermal infiltrate reveals differentially expressed canonical pathways
Häyry A; Niewold TB; Meves A; Lehman JS; Popovic-Silwerfeldt K; Charlesworth CM; Madden B; Svenungsson E; Oke V
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1596.1-151596
URINARY INTERLEUKIN (IL)-16 IN ANTI - NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS WITH KIDNEY INVOLVEMENT
Juto A; Faustini F; Hayry A; Larsson A; Malmstrom V; Bruchfeld A; Antovic A; Oke V; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1058.2-101059
PROTEOMIC ANALYSIS OF CUTANEOUS LUPUS ERYTHEMATOSUS AND DERMATOMYOSITIS DERMAL INFILTRATE REVEALS DIFFERENTIALLY EXPRESSED CANONICAL PATHWAYS
Hayry A; Niewold T; Meves A; Lehman J; Popovic-Silwerfeldt K; Charlesworth C; Madden B; Svenungsson E; Oke V
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1240.2-121240
ANTI-HISTONE AND ANTI-NUCLEOSOME ANTIBODIES, RATHER THAN ANTI-DSDNA ANTIBODIES ARE ASSOCIATED WITH INTERFERONINDUCED BIOMARKERS IN SUDANESE AND SWEDISH SLE PATIENTS
Elbagir S; Mohammed NA; Oke V; Zickert A; Larsson A; Nilsson J; Elshafie A; Svanqvist A; Westerberg C; Elagib EM; Nur MAM; Gunnarsson I; Svenungsson E; Ronnelid J
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1806
COMORBIDITY IN PSORIATIC ARTHRITIS (COMPASS) - INCIDENCE OF DEPRESSIVE SYMPTOMS AND ASSOCIATED FACTORS
Avik A; Waldheim E; Geschwind S; Antovic A; Oke V
Conference publication: 2022;:a17.1-a1a17
S12.1 Il-16 – a urinary biomarker for proliferative lupus nephritis
Häyry A; Faustini F; Zickert A; Larsson A; Sundelin B; Svenungsson E; Oke V; Gunnarsson I
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(21):11327
Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy
Idborg H; Oke V
Corrigendum: RHEUMATOLOGY. 2021;60(3):1575
Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment (vol 60, pg 1445, 2021)
Bjork A; Rodrigues RDS; Andersson ER; Sepulveda JIR; Mofors J; Kvarnstrom M; Oke V; Svenungsson E; Gunnarsson I; Wahren-Herlenius M
Preprint: RESEARCH SQUARE. 2021
Proteome Study of Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis Skin Lesions Reveals IL-16 Is Differentially Upregulated in CLE
Niewold TB; Meves A; Lehman JS; Popovic-Silwerfeldt K; Häyry A; Söderlund-Matell T; Charlesworth CM; Madden B; Lundberg IE; Wahren-Herlenius M; Svenungsson E; Oke V
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:335
SKIN PROTEOME INVESTIGATION IN CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) REVEALS NOVEL UNIQUE DISEASE PATHWAYS
Niewold T; Popovic-Silwerfeldt K; Lehman J; Meves A; Charlesworth C; Madden B; Hayry A; Antovic A; Lundberg IE; Wahren-Herlenius M; Svenungsson E; Oke V
Conference publication: LUPUS SCIENCE AND MEDICINE. 2020;7(Suppl 1):a25-A26
O32 Skin proteome investigation in cutaneous lupus erythematosus (CLE) reveals novel unique disease pathways
Niewold TB; Meves A; Lehman J; Popovic-Silwerfeldt K; Antovic A; Dorschner JM; Charlesworth CM; Lundberg I; Wahren-Herlenius M; Svenungsson E; Oke V
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2019;71
Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts
Shum J; Ghodke-Puranik Y; Tipon R; Dorschner J; Vsetecka D; Amin S; Makol A; Ernste F; Osborn T; Moder K; Chowdhary V; Thanarajasingam U; Oke V; Gunnarsson I; Zickert A; Zervou M; Svenungsson E; Goulielmos G; Niewold T
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2018;77(Suppl 2):406
THU0381 High levels of circulating type i, ii and iii interferons define distinct patient subsets with active systemic lupus erythematosus (SLE)
Oke V; Gunnarsson I; Dorschner JM; Zickert A; Niewold TB; Svenungsson E
Conference publication: 2018;:a16.1-a1a16
S4D:6 Sle comprises four immune-phenotypes, which differ regarding hla-drb1 and clinical associations
Diaz Gallo L; Lundström E; Oke V; Elvin K; Wu Y; Gustafsson J; Jönsen A; Leonard D; Zickert A; Nordmark G; Bengtsson A; Sandling J; Rönnblom L; Gunnarsson I; Yu C; Padyukov L; Svenungsson E
Conference publication: 2018;:a44.2-a4a45
PS2:26 Sle patients with secondary sjÖgren´s syndrome are characterised by typical autoantibodies and a pro-inflammatory state
Kvarnström M; Ruacho G; Gustafsson J; Zickert A; Oke V; Rönnelid J; Elvin K; Gunnarsson I; Svenungsson E
Conference publication: 2018;:a17.1-a1a17
S5A:4 Circulating type i, ii and iii interferons (ifns) associate with ifn-scores, but define distinct subsets of active sle
Oke V; Gunnarsson I; Dorschner J; Zickert A; Niewold T; Svenungsson E
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2018;70
Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
Niewold TB; Meves A; Lehman JS; Popovic-Silwerfeldt K; Charlesworth C; Wahren-Herlenius M; Svenungsson E; Oke V
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2017;76:885
SLE PATIENTS WITH SECONDARY SJOGREN'S SYNDROME ARE CHARACTERIZED BY TYPICAL AUTOANTIBODIES AND A PRO-INFLAMMATORY STATE
Kvarnstrom M; Ruacho G; Gustafsson T; Zickert A; Oke V; Ronnelid J; Elvin K; Gunnarsson I; Svenungsson E
Conference publication: LUPUS SCIENCE AND MEDICINE. 2017;4(Suppl 1):a107
233 Defining subsets in sle: the interplay among ifn-λ1, ifn-α and th17 axis cytokines
Oke V; Brauner S; Larsson A; Gustafsson J; Zickert A; Gunnarsson I; Svenungsson E
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2017;69
Patients with Secondary Sjogren's Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State
Kvarnstrom M; Ruacho G; Gustafsson J; Zickert A; Oke V; Ronnelid J; Elvin K; Gunnarsson I; Svenungsson E
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2017;69
SLE Comprises Four Immune-Phenotypes, Which Differ Regarding HLA-DRB1 and Clinical Associations
Gallo LMD; Lundstrom E; Oke V; Elvin K; Wu YL; Gustafsson J; Jonsen A; Leonard D; Zickert A; Nordmark G; Bengtsson AA; Sandling JK; Ronnblom L; Gunnarsson I; Yu C-Y; Padyukov L; Svenungsson E
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:128
INCREASED SERUM LEVELS OF IFN-Λ CORRELATE WITH TH17 AXIS CYTOKINES AND INDEPENDENTLY TO IFN-α IDENTIFY PATIENT GROUP WITH HIGHER ORGAN DAMAGE
Oke V; Brauner S; Larsson A; Gustafsson J; Zickert A; Gunnarsson I; Svenungsson E
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2016;75:430-431
MULTIPLEX SCREENING OF CYTOKINES IN THE SEARCH FOR DISEASE ACTIVITY MARKERS OF SLE
Eketjall S; Idborg H; Gustafsson JT; Zickert A; Kvarnstrom M; Oke V; Susanne P; Jakobsson P-J; Gunnarsson I; Svenungsson E
Conference publication: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2016;34(4):S45
INCREASED SERUM LEVELS OF IFN-LAMBDA 1 CORRELATE WITH TH17 AXIS CYTOKINES AND INDEPENDENTLY TO IFN-ALPHA IDENTIFY PATIENT GROUP WITH HIGHER ORGAN DAMAGE
Oke V; Brauner S; Larsson A; Gustafsson J; Zickert A; Gunnarsson I; Svenungsson E
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45:39-40
The TNF-α/p-albumin ratio: a suggested biomarker for disease activity in SLE
Svenungsson E; Eketjall S; Idborg H; Gustafsson JT; Zickert A; Kvarnstrom M; Oke V; Pettersson S; Jakobsson P-J; Gunnarsson I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2015;67
The Ratio Between TNF-a and P-Albumin - a Suggested Measure of Disease Activity in SLE
Eketjall S; Idborg H; Gustafsson J; Zickert A; Kvarnstrom M; Oke V; Pettersson S; Jakobsson PJ; Gunnarsson I; Svenungsson E
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:363
INTERFERON (IFN)-LAMBDA1/3, BUT NOT IFN-ALPHA, IS A MARKER OF POOR RESPONSE TO TREATMENT IN LUPUS NEPHRITIS
Zickert A; Oke V; Parodis I; Svenungsson E; Gunnarsson I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:188
HIGH SERUM LEVELS OF IFN-LAMBDA1/3 AND IFN-ALPHA CHARACTERIZE TWO SEPARATE SUB-GROUPS AMONG SLE PATIENTS
Oke V; Gustafsson J; Zickert A; Gunnarsson I; Svenungsson E
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2014;43:86-87
High serum levels of IFN-λ1/3 and IFN-α characterize two separate subgroups among SLE patients
Oke V; Gustafsson J; Brauner S; Zickert A; Gunnarsson I; Svenungsson E
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2014;43:10
Interferon (IFN)-λ1/3, but not IFN-α, is a marker of poor response to treatment in lupus nephritis
Zickert A; Oke V; Parodis I; Svenungsson E; Gunnarsson I
Review: JOURNAL OF INTERNAL MEDICINE. 2013;273(6):544-554
Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis
Oke V; Wahren-Herlenius M
Review: JOURNAL OF AUTOIMMUNITY. 2012;39(1-2):77-82
The immunobiology of Ro52 (TRIM21) in autoimmunity: A critical review
Oke V; Wahren-Herlenius M
Thesis / dissertation: 2011
Studies on molecular regulation of inflammation in cutaneous lupus erythematosus
Oke, Vilija
Conference publication: ARCHIVES OF DERMATOLOGICAL RESEARCH. 2009;301(1):47
High Expression of Ro52 in Skin Lesions in Cutaneous Lupus Erythematosus
Oke V; Strandberg L; Nyberg F; Wahren-Herlenius M
Visa fler

Forskningsbidrag

Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT), randomised double-blind placebo controlled randomised trial (RCT)
Swedish Research Council
1 January 2024 - 31 December 2024
Increased risk for thrombotic complications in patients with rheumatic diseases -from register data to individual patient and biomarkers
Stockholm County Council and Karolinska Institutet (ALF)
1 January 2024 - 31 December 2025

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2011

Uppdrag

Sektionsansvarig, Research and medical student education, Medicine, Rheumatology, Karolinska Institute, 2023-

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Uppdrag

Nyheter från KI

Kalenderhändelser från KI